Guí a OncoSur de me l anoma 62 > 16. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvanttherapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2013;102(7):493-501. 17. Eggermont AMM, Rutkowski P, Dutriaux C, et al. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. Eur J Cancer 2020;133:94-103. 18. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of Stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 trial. Eur J Cancer 2019;119:1-10. 19. Tarhini AA, Lee SJ, Hodi FS, et al. Phase III randomized study of adjuvant ipilimumab (3 or 10 mg/Kg) versus high-dose interferon-alfa2b for resected high-risk melanoma. North American Intergroup E1609. J Clin Oncol 2020;38:567-75. 20. Ascierto PA, Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III B-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomisez, controlled, phase 3 trial. Lancet Oncol 2020;21:1465-77. 21. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018;378:1789-801. 22. Eggermont AMM, Blank CU, Mandala M, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325MG/Keynote 054 double-blinded phase III trial. ESMO 2020, abstract LBA46. 23. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358-72. DOI: 10.1016/S14702045(20)30062-0 24. Dummer R, Hauschild A, Santinami M et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383:1139-48. 25. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018;19:510. 26. Rao NG, Yu HH, Trotti A 3rd, et al. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 2011;20:115. 27. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 2015;16:1049. 28. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 1991;64:1147. 29. KEYNOTE-716 (NCT03553836). Available from: https://clinicaltrials.gov/ct2/show/NCT03553836?term=KEYNOTE-716&draw=2&rank=1 (Revisado en noviembre 2021).
RkJQdWJsaXNoZXIy OTI4NTYw